Flaviviruses replicate within the cytosol of infected cells, a site distant from the nucleus where the nuclear pore complex typically operates. Historically, NUP98 and NUP153 were known for their roles as gatekeepers regulating molecular traffic between the nucleus and cytoplasm, not for involvement in cytosolic viral processes. This new research challenges that notion, demonstrating that both nucleoporins relocate to viral replication sites within the cytosol during infection, directly binding viral RNA. Moreover, NUP153 uniquely binds viral proteins, implicating it as a multifaceted facilitator of viral propagation.

Viruses, due to their limited genomes, rely extensively on hijacking host cell machinery for replication and protein synthesis. Understanding host factors that are co-opted during infection presents a promising avenue for therapeutic intervention, particularly as antiviral drug development has lagged behind for many flaviviruses. These pathogens cause millions of infections annually without approved targeted antiviral treatments, underscoring the urgent need for novel strategies that go beyond traditional antiviral modalities.

The researchers employed a combination of molecular biology techniques, including RNA-protein interaction assays and cellular imaging, to analyze the recruitment and binding dynamics of NUP98 and NUP153 during flavivirus infection. Their findings elucidate distinct roles for each nucleoporin: NUP98 is essential for efficient viral RNA replication, while NUP153 regulates the relative abundance of viral structural and non-structural proteins. This balance is crucial for successful viral assembly and infection progression.

Of particular interest is the discovery that NUP153 interacts with a specific segment of the viral RNA located at the junction between sequences encoding structural proteins and those encoding non-structural proteins. This selective binding modulates the translation of viral proteins, ensuring proper stoichiometric ratios, a mechanism that contradicts the previous assumption that viral protein synthesis proceeds at uniform rates. The ability of the virus to fine-tune protein production via host cell factors highlights a sophisticated level of host-pathogen interplay that has not been appreciated before.

An innovative aspect of this research comes from collaborative efforts with Uppsala University, where a synthetic peptide was identified that can block the binding of NUP98 to viral RNA. By disrupting this critical interaction, viral replication was significantly impaired, demonstrating that targeting host-virus protein interfaces can yield potent antiviral effects. This finding opens the door to therapeutic designs that focus on host factors, potentially circumventing issues of viral mutation and drug resistance commonly seen with direct-acting antivirals.

The recruitment of nucleoporins to cytosolic replication platforms signifies a paradigm shift in our understanding of flavivirus biology. Rather than being confined to nuclear pore functions, these proteins moonlight as integral components of the viral replication machinery. This dual role adds complexity to the nuclear pore proteins but also offers new targets for precision antivirals. Therapeutics that inhibit nucleoporin-virus interactions could present a broad-spectrum strategy against diverse flaviviruses.

Targeting stable host proteins presents an attractive alternative to conventional antivirals that often lose efficacy due to rapid viral evolution. Host proteins are less prone to mutation-driven resistance, lending durability to treatment strategies that exploit this aspect. Furthermore, because NUP98 and NUP153 are implicated across related orthoflaviviruses, drugs designed against these host factors could tackle multiple diseases simultaneously, amplifying their clinical utility.

This research underscores the importance of interdisciplinary approaches that blend virology, molecular biology, and structural biology to decode complex infection processes. Advancing our knowledge of how human proteins facilitate viral lifecycles helps identify vulnerabilities in the pathogen that were previously concealed. Continued exploration of nucleoporin functions may also reveal broader implications for cell biology and host defense mechanisms.

Professor Anna Överby Wernstedt and her team’s work represents a significant step forward in antiviral drug discovery. Their studies not only deepen the molecular understanding of flavivirus replication but also provide proof-of-concept for targeting host-virus interactions with synthetic molecules. As flavivirus-related diseases continue to pose global health threats, innovative solutions such as these are critical for developing next-generation therapeutics.

In sum, by redefining the roles of nuclear pore proteins NUP98 and NUP153 in flavivirus infection, this research dismantles old paradigms and charts new paths for antiviral intervention. The dual functionality of these nucleoporins—transitioning from nuclear gatekeepers to viral facilitators—demonstrates the virus’s ability to repurpose cellular machinery with remarkable precision. These insights set the stage for transformative antiviral strategies that focus on host factors, potentially revolutionizing how we confront viral diseases in the future.

Subject of Research: Cells
Article Title: Proviral NUP153 binding to viral proteins and RNA regulates structural–nonstructural protein ratios in orthoflavivirus infection.
News Publication Date: 8-Apr-2026
Image Credits: Mattias Pettersson
Keywords: Viral infections, West Nile virus, Cell biology, Life sciences, Health and medicine

At the heart of the viral life cycle lies an intricate exploitation of host cell machinery. Viruses like SARS-CoV-2 hijack cellular lipid metabolism to form membranous replication organelles, structures indispensable for efficient replication. Cholesterol, a fundamental component of these membrane microdomains, orchestrates the spatial organization and fluidity crucial for viral replication complexes. By modulating cholesterol metabolism, the virus creates an optimal environment for its propagation. The current investigation reveals that tetrandrine disrupts this viral stratagem by altering cholesterol distribution within host cells, thereby obstructing the formation of these vital replication platforms.

Autophagy, a conserved cellular catabolic process, serves as a double-edged sword in viral infections. While some viruses subvert autophagic pathways for their benefit, others are compromised by heightened autophagic flux which degrades viral components or restricts their replication niches. Tetrandrine’s capacity to induce autophagy emerges as a pivotal antiviral mechanism. The researchers demonstrated that treatment with tetrandrine significantly elevates markers of autophagic activity, including increased LC3-II accumulation and enhanced autophagosome formation. Intriguingly, this autophagic induction occurs concomitantly with a marked reduction in viral RNA levels and infectious virion production.

Delving deeper into the molecular intricacies, the study highlights the role of the insulin-like growth factor (IGF) signaling pathway, a critical regulator of cellular metabolism, growth, and survival. The IGF axis has been implicated in the pathophysiology of multiple viral infections through its capacity to influence metabolic reprogramming. Evidence from this study indicates that tetrandrine suppresses IGF receptor expression and downstream signaling cascades, including the PI3K/Akt/mTOR pathway, which is known to negatively regulate autophagy. By dampening IGF signaling, tetrandrine effectively releases the autophagy brake enforced by mTOR, thus promoting a cellular environment hostile to viral replication.

The confluence of cholesterol depletion and IGF signaling suppression orchestrated by tetrandrine creates a unique antiviral state. The disruption of cholesterol-enriched lipid rafts impairs the viral entry and replication complex assembly, while autophagy activation facilitates the clearance of viral components. Moreover, the attenuation of IGF-mediated survival signals may sensitize infected cells to autophagy-dependent degradation processes. These combined effects culminate in a formidable blockade of SARS-CoV-2 replication, as verified through quantitative PCR assays, plaque-forming unit counts, and electron microscopy imaging presented in the study.

Beyond the immediate antiviral effects, tetrandrine’s modulation of these fundamental cellular pathways underscores its potential as a broad-spectrum antiviral agent. Cholesterol metabolism and IGF signaling are exploited by a variety of viral pathogens, suggesting that tetrandrine or derivatives thereof could exert efficacy against other viruses with similar replication strategies. This opens exciting prospects for developing host-directed therapies, which circumvent the issue of viral mutational escape often observed with direct-acting antivirals.

Importantly, the study meticulously addresses the safety profile of tetrandrine, an aspect critical for translational potential. Cytotoxicity assays reveal that therapeutic concentrations sufficient to inhibit viral replication exhibit minimal adverse effects on host cell viability. This therapeutic window is particularly noteworthy given tetrandrine’s historical use in traditional medicine and emerging clinical investigations in fibrotic and inflammatory diseases.

Mechanistically, the study employs a combination of molecular biology techniques, including siRNA-mediated knockdown experiments and pharmacological inhibitors, to dissect the pathways influenced by tetrandrine. Knocking down key autophagy genes such as ATG5 markedly diminishes the antiviral efficacy of tetrandrine, affirming the centrality of autophagy in its mechanism of action. Moreover, restoring IGF signaling counteracts the antiviral effects, reinforcing the interplay between IGF downregulation and autophagy activation as a critical axis.

The implications of these findings extend into the therapeutic landscape of COVID-19 management. Current treatments largely target viral proteins directly, but the rapid evolution of SARS-CoV-2 variants has compromised their long-term effectiveness. Host-directed agents like tetrandrine could provide a resilient alternative by targeting cellular pathways less prone to viral mutations. This strategy may also synergize with existing antiviral drugs, enhancing their efficacy and mitigating resistance.

In the context of global health, tetrandrine’s relative accessibility and cost-effectiveness may facilitate widespread deployment, particularly in resource-limited settings disproportionately impacted by the pandemic. However, the authors prudently caution that rigorous clinical trials are requisite to validate efficacy and safety in humans, as in vitro and preclinical findings might not always translate seamlessly.

Furthermore, this study contributes to the broader understanding of viral pathogenesis and host defense. It accentuates the complexity of cellular metabolic networks exploited by viruses and highlights autophagy as a versatile tool within the antiviral arsenal. These insights may invigorate research into other bioactive natural products capable of modulating similar pathways, fostering a rich pipeline of potential therapeutics.

The integration of advanced omics technologies and high-resolution imaging in the study enabled the precise mapping of tetrandrine’s effects at cellular and molecular scales. Such interdisciplinary approaches exemplify the cutting-edge methodologies propelling antiviral research forward, offering a model for future investigations seeking to unravel virus-host dynamics.

Given the persistent threat posed by emerging viral diseases, the importance of identifying compounds that can robustly induce protective cellular states cannot be overstated. Tetrandrine’s dual action on cholesterol and IGF pathways positions it as a promising candidate in the antiviral armamentarium, warranting accelerated exploration.

In summary, Marchioro et al.’s research marks a significant advance in the fight against SARS-CoV-2, unveiling tetrandrine as a potent modulator of autophagy that cripples viral replication by targeting essential metabolic and signaling pathways. The findings illuminate a path toward host-centric antiviral strategies that could reshape therapeutic paradigms not only for COVID-19 but potentially for a wide spectrum of viral infections that threaten global health.

Subject of Research: SARS-CoV-2 replication inhibition via tetrandrine-driven autophagy and modulation of cholesterol and IGF signaling pathways.

Article Title: Tetrandrine-driven autophagy suppresses SARS-CoV-2 replication by modulating cholesterol and IGF signaling pathways.

Article References:
Marchioro, L.d.O., De Stefanis, S., Araújo, B.G. et al. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-025-02926-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02926-7